Revolution Medicines Warrant(Rvmdw) Financials: Return On Equity Compared To Industry Average, Plus Other Key Ratios

Profitability Trend (Last 5 Years)

Profitability - return on equity

This chart shows the historical trend of return on equity for RVMDW compared to its industry average over the recent years.

Ratio Definition and Interpretation

Name: Return on Equity (ROE)

Definition: ROE shows how much profit the company earns for its shareholders based on their invested equity. It’s one of the most watched profitability ratios. A consistently high ROE signals strong management and efficient use of shareholder capital. But artificially high ROE may sometimes be boosted by excessive debt.

Interpretation:
• In '2021', RVMDW's return on equity was -31.1%, measuring profitability for shareholders. Industry average for nan in '2021' stood at -10.0%.
• In '2022', RVMDW's return on equity was -38.6%, measuring profitability for shareholders. The decline from '2021' may indicate some operational or financial challenges. Industry average for nan in '2022' stood at 12.8%. Industry average increased by 22.8% compared to previous year.
• In '2023', RVMDW's return on equity was -34.8%, measuring profitability for shareholders. The increase since '2022' reflects strengthening financial performance. Industry average for nan in '2023' stood at 26.9%. Industry average increased by 14.1% compared to previous year.
• In '2024', RVMDW's return on equity was -29.3%, measuring profitability for shareholders. The increase since '2023' reflects strengthening financial performance. Industry average for nan in '2024' stood at -20.5%. Industry average declined by 47.4% from previous year.
Overall, RVMDW's return on equity has been volatile but generally stable over the past 4 years.

Formula: ROE = Net Income / Shareholders' Equity

Good Range: 10%-20% desirable for many industries.